PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
FULC vs. BIOX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between FULC and BIOX is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

FULC vs. BIOX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Fulcrum Therapeutics, Inc. (FULC) and Bioceres Crop Solutions Corp. (BIOX). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-56.93%
-32.34%
FULC
BIOX

Key characteristics

Sharpe Ratio

FULC:

-0.57

BIOX:

-1.19

Sortino Ratio

FULC:

-0.23

BIOX:

-1.95

Omega Ratio

FULC:

0.96

BIOX:

0.77

Calmar Ratio

FULC:

-0.58

BIOX:

-0.78

Martin Ratio

FULC:

-1.07

BIOX:

-1.42

Ulcer Index

FULC:

49.06%

BIOX:

34.08%

Daily Std Dev

FULC:

92.43%

BIOX:

40.38%

Max Drawdown

FULC:

-92.70%

BIOX:

-62.25%

Current Drawdown

FULC:

-87.67%

BIOX:

-57.25%

Fundamentals

Market Cap

FULC:

$206.05M

BIOX:

$413.50M

EPS

FULC:

-$0.29

BIOX:

$0.02

Total Revenue (TTM)

FULC:

$80.00M

BIOX:

$300.91M

Gross Profit (TTM)

FULC:

$62.26M

BIOX:

$125.90M

EBITDA (TTM)

FULC:

$3.76M

BIOX:

$36.85M

Returns By Period

In the year-to-date period, FULC achieves a -18.72% return, which is significantly lower than BIOX's 12.50% return.


FULC

YTD

-18.72%

1M

-24.80%

6M

-56.93%

1Y

-51.95%

5Y*

-25.65%

10Y*

N/A

BIOX

YTD

12.50%

1M

6.88%

6M

-32.34%

1Y

-45.76%

5Y*

6.24%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

FULC vs. BIOX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FULC
The Risk-Adjusted Performance Rank of FULC is 2020
Overall Rank
The Sharpe Ratio Rank of FULC is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of FULC is 2626
Sortino Ratio Rank
The Omega Ratio Rank of FULC is 2424
Omega Ratio Rank
The Calmar Ratio Rank of FULC is 1313
Calmar Ratio Rank
The Martin Ratio Rank of FULC is 2020
Martin Ratio Rank

BIOX
The Risk-Adjusted Performance Rank of BIOX is 44
Overall Rank
The Sharpe Ratio Rank of BIOX is 11
Sharpe Ratio Rank
The Sortino Ratio Rank of BIOX is 22
Sortino Ratio Rank
The Omega Ratio Rank of BIOX is 33
Omega Ratio Rank
The Calmar Ratio Rank of BIOX is 55
Calmar Ratio Rank
The Martin Ratio Rank of BIOX is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

FULC vs. BIOX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Fulcrum Therapeutics, Inc. (FULC) and Bioceres Crop Solutions Corp. (BIOX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for FULC, currently valued at -0.57, compared to the broader market-2.000.002.004.00-0.57-1.19
The chart of Sortino ratio for FULC, currently valued at -0.23, compared to the broader market-4.00-2.000.002.004.006.00-0.23-1.95
The chart of Omega ratio for FULC, currently valued at 0.96, compared to the broader market0.501.001.502.000.960.77
The chart of Calmar ratio for FULC, currently valued at -0.58, compared to the broader market0.002.004.006.00-0.58-0.78
The chart of Martin ratio for FULC, currently valued at -1.07, compared to the broader market-10.000.0010.0020.00-1.07-1.42
FULC
BIOX

The current FULC Sharpe Ratio is -0.57, which is higher than the BIOX Sharpe Ratio of -1.19. The chart below compares the historical Sharpe Ratios of FULC and BIOX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-2.00-1.000.001.002.00SeptemberOctoberNovemberDecember2025February
-0.57
-1.19
FULC
BIOX

Dividends

FULC vs. BIOX - Dividend Comparison

Neither FULC nor BIOX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

FULC vs. BIOX - Drawdown Comparison

The maximum FULC drawdown since its inception was -92.70%, which is greater than BIOX's maximum drawdown of -62.25%. Use the drawdown chart below to compare losses from any high point for FULC and BIOX. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%SeptemberOctoberNovemberDecember2025February
-87.67%
-57.25%
FULC
BIOX

Volatility

FULC vs. BIOX - Volatility Comparison

The current volatility for Fulcrum Therapeutics, Inc. (FULC) is 14.17%, while Bioceres Crop Solutions Corp. (BIOX) has a volatility of 15.75%. This indicates that FULC experiences smaller price fluctuations and is considered to be less risky than BIOX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
14.17%
15.75%
FULC
BIOX

Financials

FULC vs. BIOX - Financials Comparison

This section allows you to compare key financial metrics between Fulcrum Therapeutics, Inc. and Bioceres Crop Solutions Corp.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab